GLP-1产业链迎重要催化,全球最大糖尿病会议举办在即

金融界
Jun 10

近日,据美国糖尿病协会(ADA)官网显示,其第85届科学年会将于6月20-23日在美国芝加哥McCormick会展中心举行,该会议被誉为“全球规模最大的糖尿病会议”。期间将有超过200场专题报告展示糖尿病科学的方方面面,尤其是GLP-1类药物的多靶点升级与减重治疗新策略。

该药物联合司美格鲁肽的II期试验数据读出,旨在对比Bima联合司美和单用司美的疗效和安全性。研究主要试验终点是48周时的体重变化。次要试验终点包括腰围、体脂肪、瘦体重、腰高比、安全性等。

中航证券表示,肥胖和超重带来潜在心血管、代谢、肿瘤等疾病风险,现有手段主要包括生活干预、药物治疗、手术治疗。未来GLP-1受体激动剂有望成为肥胖适应症市场领军药物,从药企在减肥领域的研发布局和进展考虑,布局更加完整、疗效突出、有先发优势的企业或率先受益。浙商证券表示,GLP-1药物的适应症从降血糖向减重、NASH、阿尔茨海默症等蓝海领域快速推进,市场空间有望超预期,减肥药蓝海市场空间广阔。

责任编辑:栎树

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10